Pharmacophore Modeling and Three Dimensional Database Searching for Drug Design Using Catalyst: Recent Advances

    November 2004 in “ Current Medicinal Chemistry
    Osman Güner, Omoshile Clement, Yasuhisa Kurogi
    Image of study
    TLDR The document concludes that Catalyst software is effective for drug design, identifying potent compounds for various medical conditions.
    The document from 2004 highlights the use of Catalyst software in pharmacophore modeling and 3D database searching for drug design, showcasing several studies that demonstrate its effectiveness. One study identified a potent COX-2 inhibitor with an IC50 of 0.65 μM, while another developed a model for Mycobacterium avium complex dihydrofolate reductase inhibitors with high classification accuracy. A model for non-steroidal 5α-Reductase inhibitors, relevant for conditions like benign prostate hyperplasia and androgenic alopecia, identified 37 promising compounds. The document also details the creation of a pharmacophore model for serotonin reuptake inhibitors with a high correlation coefficient of 0.921 and the ability to differentiate between enantiomers of citralopram. Additionally, a model for adrenergic receptor antagonists was developed with a correlation coefficient of 0.92. The importance of CYP17 inhibitors for prostate cancer treatment is discussed, with new potent compounds identified through pharmacophore modeling. The document also mentions the search for dual inhibitors for Alzheimer's Disease and potent inhibitors for integrin VLA-4, with the most potent having an IC50 of 1.3 nM, as well as patents for selective serotonin re-uptake inhibitors with minimal CYP2D6 inhibition.
    Discuss this study in the Community →

    Related Community Posts Join

    6 / 127 results
      FCE 28260: A Forgotten 5α-Reductase Inhibitor

      community FCE 28260: A Forgotten 5α-Reductase Inhibitor

      in Research  330 upvotes 11 months ago
      FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

      community Massive study on finasteride side effects released

      in Finasteride/Dutasteride  83 upvotes 2 years ago
      The release of a study on 5a-reductase inhibitors (finasteride and dutasteride) which showed an increased risk of depression, dementia, decreased libido, and reduced semen load as potential side effects; discussion around other forms of hair loss treatments such as topical minoxidil, RU58841, or opting to accept baldness; and advice to consider professional help for deeper issues related to hair loss.

    Similar Research

    5 / 1000+ results